Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. NUWE
NUWE logo

NUWE Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Nuwellis Inc (NUWE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
1.350
1 Day change
3.85%
52 Week Range
50.820
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Nuwellis Inc (NUWE) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock shows weak financial performance, bearish technical indicators, and lacks positive catalysts or strong trading signals. Additionally, the stock's trend predicts further declines in the short and medium term, making it unsuitable for long-term growth-focused investment.

Technical Analysis

The technical indicators for NUWE are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 30.29, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 1.439), with resistance levels at R1: 1.813 and R2: 1.929. Overall, the technical setup suggests further downside risk.

Positive Catalysts

  • NULL identified. No recent news, no significant insider or hedge fund activity, and no positive trading signals.

Neutral/Negative Catalysts

  • Weak financial performance in Q3 2025, with revenue down -6.34% YoY, net income down -80.11% YoY, EPS down -99.24% YoY, and gross margin down -6.83% YoY. Stock trend analysis predicts a -5.02% decline in the next week and -13.95% in the next month.

Financial Performance

In Q3 2025, Nuwellis Inc reported declining financials. Revenue dropped to $2,217,000 (-6.34% YoY), net income fell to $469,000 (-80.11% YoY), EPS plummeted to 0.56 (-99.24% YoY), and gross margin decreased to 65.18 (-6.83% YoY). These trends indicate significant financial challenges.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available.

Wall Street analysts forecast NUWE stock price to rise
1 Analyst Rating
Wall Street analysts forecast NUWE stock price to rise
0 Buy
1 Hold
0 Sell
Hold
Current: 1.300
sliders
Low
5.5
Averages
5.5
High
5.5
Current: 1.300
sliders
Low
5.5
Averages
5.5
High
5.5
Roth Capital
Jonathan Aschoff
Buy
downgrade
$13 -> $11
AI Analysis
2025-05-13
Reason
Roth Capital
Jonathan Aschoff
Price Target
$13 -> $11
AI Analysis
2025-05-13
downgrade
Buy
Reason
Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Nuwellis to $11 from $13 and keeps a Buy rating on the shares. While the company's Q1 revenue was down 18% quarter over quarter, pediatric utilization grew 38% year over year, the analyst tells investors in a research note. The firm believes that the four-fold increase in Aquadex Centers for Medicare & Medicaid Services reimbursement should support future revenue growth.

People Also Watch